Pelagos Insurance Capital Limit PLGO

Reference table

1. What it is

Pelagos Insurance Capital Limited (NYSE: PLGO) is a Bermuda-headquartered specialty insurance and reinsurance company. It operates two segments: Insurance — property, marine, asset-backed finance, portfolio credit, aviation & aerospace, political risk, violence & terror, energy, cyber, and other specialty lines — and Reinsurance — property reinsurance, retrocession, and whole-account reinsurance. Founded 2014; renamed from Fidelis Insurance Holdings Limited to Pelagos Insurance Capital in May 2026; IPO on the NYSE 2023-06-29. Headquarters Pembroke, Bermuda; CEO Daniel (Dan) Burrows; 108 full-time employees — a deliberately lean underwriting balance sheet, not a distribution machine. Calendar fiscal year.

Business-mix caveat (honest data gap): the data file's product-segment and geographic-segment tables are empty for PLGO, so we cannot quantify the Insurance vs Reinsurance split or geographic exposure from this dataset — the description above is qualitative, from the company profile. Standard insurance KPIs (combined ratio, net premiums written/earned split, reserve development) are also not in the file; we work from the GAAP statements provided.

2. The expert thesis — why the panel is bullish (traceable)

No expert-panel coverage — this note is fundamentals-driven. The Synthos KB contains zero traceable claims on PLGO (0 voices, 0 claims, breadth 0). That is the honest house standard for screen-surfaced names: this ticker entered the pipeline through a quant momentum screen, not through conviction voices, and nothing below leans on expert authority. There is likewise no management-guidance claim ingested (PLGO_mgmt does not exist in the KB). Everything in this note reconciles to the FMP data file; where a figure is missing, we say so.

Consequences for how you should read this dive:

• Conviction rating: None. There is no panel to weight, no skill scores, no countervailing short thesis — the bear case in §3 is built entirely from the reported numbers.
• Coverage is thin on the Street too: the estimates carry 1 revenue analyst and 2–5 EPS analysts per year, and the price-target set spans just $22.00–$22.50. Treat both as weak signals, not consensus in any deep sense.

3. Synthos scores & the Bull / Base / Bear cases

The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):

The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is the expected path; the cases bound the range.

Synthos fair value = the base case, ~$24 (−3%), full range $18–$29. Our base sits above the Street's $22.25 consensus target — we give more credit to the 1.0×-book floor and the buyback than the two-to-five analysts in the price action do — but both agree on the essential point: at $24.63 the upside is not being paid for the cat risk you're underwriting. Valuation method, labeled: this is a book-value / earnings-multiple anchor (1.0× BVPS cross-checked against 6.5× forward EPS), not a DCF — the FY25 operating cash flow of −$408M makes a cash-flow DCF meaningless for an insurer with lumpy claim timing (FMP's own DCF score is 1/5 for the same reason). This is a tracked call — the Forecaster Scorecard grades it once it matures.

4. Exponential Potential

Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). PLGO is neither, honestly — it is a capital-return value name:

• Forward growth: EPS estimates rise $3.66 → $4.15 → $4.66 (2026E→2028E), a ~13% CAGR — respectable, but revenue estimates fall from $3.81B (2027E) to $3.34B (2028E), so the EPS growth is margin/buyback math, not expansion.
• Acceleration (2nd derivative): negative-to-flat. The earnings recovery from the cat-hit FY2024–H1-2025 stretch is a normalization, not an acceleration; once normalized, growth is the insurance pricing cycle.
• Room to run: at $2.1B market cap the constraint isn't size — it's business model. Insurers re-rate to a ceiling (a good specialty franchise earns ~1.2–1.5× book); they don't compound multiples.
• Estimate-basis caveat: the revenue estimates ($3.3–3.8B) sit far above income-statement revenue ($2.17B FY25) and the earnings-calendar "revenue actuals" (e.g., $1.84B in a single quarter) — these lines appear to mix gross premiums written vs net earned revenue. We flag it rather than reconcile what the file can't: trust the EPS lines, treat the revenue lines with caution.

Exponential Potential: Low (2/10). You would own PLGO for the yield-plus-buyback-plus-re-rate path, not for a moonshot — and that path maxes out around our $29 bull case.

5. Financials (real numbers — FMP annual/quarterly)

• Revenue (income statement, net basis): FY25 $2.17B, +2.9% (FY24 $2.11B). FY23's $3.37B is not a clean comp — see the one-time flag below.
• The FY23 distortion (read carefully): FY23 shows net income $2.13B / EPS $18.65 on $3.37B revenue, with the cash-flow statement reconciling −$1.72B of "other non-cash items" and a negative tax expense — i.e., the headline was dominated by a very large non-cash/one-time gain (booked around the IPO-era restructuring). Underwrite the FY24–FY25 run-rate, not FY23.
• Quarterly trajectory (the lumpiness on display): Q4-24 −$122.2M (EPS −$1.09, cost of revenue exceeded revenue — a catastrophe-loss quarter) → Q1-25 −$42.5M (−$0.38) → Q2-25 +$19.7M → Q3-25 +$130.5M ($1.24) → Q4-25 +$117.8M ($1.17) → Q1-26 +$108.0M ($1.15 diluted). Four straight profitable quarters; trailing-twelve-month diluted EPS ≈ $3.74.
• Margins (TTM): net margin 17.7%, EBIT margin 22.7%, "gross" margin 39.0% (for an insurer this is essentially revenue less losses & underwriting costs — read it as loss-experience, not product economics).
• Cash flow — the honest wart: FY25 operating cash flow −$408.3M (FCF −$409.5M) despite $225.5M of net income, driven by a −$589M working-capital swing (claims/receivables timing). FY24 OCF was +$618M and FY23 +$495M — insurance cash flow is timing-lumpy, but a negative-OCF year alongside $321M of buybacks funded partly by +$393M of new short-term debt is a capital-allocation tension worth naming (§9). The TTM free-cash-flow yield of 14.1% in the ratio file reflects a different (TTM) window than the FY25 statement — the two are inconsistent on their face; we flag rather than smooth it.
• Balance sheet: cash + short-term investments $1.45B, total investments $3.24B, total debt $843M (up from $507M), net debt ≈ −$30M (net cash). Equity $2.40B → BVPS $24.25. Financial leverage 4.75× assets/equity — normal for an insurer, but it is leverage. Receivables of $5.16B and deferred revenue of $4.38B are (re)insurance balances (recoverables/unearned premium); the 761-day "DSO" in the ratio file is an artifact of applying industrial metrics to an insurer — ignore it.
• Per-share capital return: shares out 116.5M (FY22) → 93.0M (Q1-26), −20%. FY25: $321M buybacks + $52.3M dividends ≈ $373M returned, ~18% of today's market cap in one year. Dividend $0.60/share, 2.44% yield, payout ratio ~14%.

6. Valuation — priced in or room?

On every static multiple PLGO screens cheap: 6.5× trailing EPS, ~6.7× 2026E, ~5.9× 2027E, ~5.3× 2028E; 1.02× book; 0.99× sales; EV/EBITDA 3.9× (EV metrics are of limited meaning for insurers, noted for completeness); earnings yield 16.4%; FMP letter rating A− (overall 4/5 — though its DCF sub-score is 1/5, consistent with the negative-OCF year). The Graham number in the file is $46.97, ~1.9× the price — a blunt instrument, but directionally it says "asset-cheap."

So why isn't this a Buy? Three reasons the multiple is low for cause: (1) earnings volatility — two losing quarters in six; a 6.5× P/E on cat-exposed earnings is not the same as 6.5× on software earnings; (2) the re-rate already happened — the stock is within 4% of its 52-week high and (per the quote's full-year range) ~66% above its $14.80 low; (3) the Street's own targets sit at $22.00–$22.50, ~10% below the price, with a genuinely split tape (2 Buy / 2 Hold / 2 Sell — the file's "consensus: Buy" label overstates a coin-flip distribution). Fair value ~$24 ≈ book: at 1.0× book you are paid the ROE minus the cat losses you absorb; below ~0.85× book (~$21) the same math starts paying you a margin of safety. That's the trigger.

7. Technicals (from the tech block)

• Trend: up. $24.63 sits above the 50-DMA ($22.47) and above FMP's 200-day average ($19.76 — the file's own 200-DMA computation is null because the local price window is shorter than 200 sessions; we cite the quote-block figure and say so). MACD +0.75 (positive).
• Location: −3.6% off the 52-week high ($25.56 in the tech window; $25.60 in the quote) and +22% off the tech-window low ($20.14); the quote block's full-year range is wider ($14.80–$25.60), implying ~+66% off the true 12-month low. The two ranges disagree because the tech block covers a shorter history — flagged, not smoothed. Max drawdown from peak in the window: only −3.6% — this has been a steady grinder, not a spike.
• Momentum: RSI(14) 58 — neutral-positive, not overbought.
• Relative strength: 3/6/12-month stock returns are null in the file (insufficient history in the computation window), so no honest relative-strength read vs SPY (+21.1% 12-mo) or QQQ (+31.2%) is possible. What we can say: a low-beta (0.30) financial sitting 4% from its high in a strong tape is relative strength of a quiet kind.
• Read: technicals are constructive but late — an intact uptrend near highs with neutral momentum. For a Watch name, that argues patience: the buy case improves on a pullback toward the 50-DMA (~$22.50) or the ~$21 trigger, not at the high.

8. Moat & competitive position

Pelagos's edge, such as it is, is underwriting selection in hard-to-price specialty lines (political violence, aviation war, marine, cyber, retro) with a lean 108-person team — a model where the moat is the underwriting culture and broker relationships, not scale. That is a real but fragile advantage: specialty pricing is cyclical, capacity floods in after good years, and a lean shop has key-person concentration. The mid-teens ROE and four straight profitable quarters say the model currently works; the Q4-24/Q1-25 losses say it works until the tail event.

Peer set: the data file's peer list is empty — an honest gap. The natural comparators (Bermuda specialty/reinsurance names) are not supplied, so no relative-multiple table is offered here rather than inventing one. Directionally, 1.0× book with ~16% ROE is not demanding versus the specialty cohort's historical range, but we cannot show that from this file.

9. Management, capital allocation & guidance

• Capital allocation — aggressive return, with a tension. FY25: $321M repurchased (at prices well below today's, and below book — accretive) plus $52.3M dividends, against negative $408M operating cash flow, bridged by $393M of new short-term borrowings. Buying back stock below book is good math; funding it with debt in a negative-cash-flow year is the kind of decision that looks smart until a cat year — flagged as the central capital-allocation question for the 2026-08-12 call.
• Insider activity: the only Form 4 in the file (2026-06-03) is Jonathan Strickle, Group Managing Director — 2,881 shares withheld at $21.58, transaction type "F-InKind" (tax withholding on vesting), leaving 137,305 shares owned. That is routine, not a discretionary sale. No open-market insider buys or sells appear in the file — a neutral, thin signal.
• Management guidance: none ingested — there is no PLGO_mgmt voice in the KB and no guidance text in the data file. The earnings calendar shows a pattern of EPS beats: 0.94 vs 0.75 est (2026-05-13), 1.09 vs 1.06 (2026-02-25), 1.21 vs 1.19 (2025-11-12), 0.12 vs −0.39 (2025-08-13). Note the calendar's EPS actuals (operating basis, e.g. $0.94 for Q1-26) run below the GAAP diluted EPS in the income statement ($1.15 same quarter) — two different earnings bases; we cite both rather than pick silently. The calendar's revenue estimates are visibly unreliable (e.g., actual $1.84B vs $903M "estimate") — basis mismatch, disregard that line.
• The rebrand: Fidelis → Pelagos (May 2026). The file offers no stated rationale. A rename one year into a public listing is at minimum a monitoring item (brand/franchise continuity with brokers matters in specialty lines).

10. Catalysts & what to watch

• Next earnings: 2026-08-12 (Q2 2026; Street EPS est $0.94). Key lines: catastrophe/large-loss experience, whether the buyback pace held, and whether operating cash flow turned positive.
• Atlantic hurricane season (now → November): the single largest swing factor for a property-cat-exposed book. A benign season is itself a catalyst — it de-risks the year and supports the bull case.
• Buyback cadence: FY25's ~$373M total return was ~18% of the market cap; continuation below ~1.1× book keeps compounding BVPS. A halt would be a tell.
• Reserve development / large specialty losses: aviation, political violence, and cyber are headline-driven lines; watch for one-off loss disclosures.
• Post-rebrand franchise evidence: premium retention and broker flow under the Pelagos name.

Thesis tripwires (what would change the call): a catastrophe quarter that prints a loss anywhere near the Q4-24 scale (−$1.09 EPS); a second consecutive negative-OCF year; buybacks suspended while debt keeps rising; or the price falling to ~$21 — which flips this from Watch toward an actionable entry, per the strategic line.

11. Key risks

• Catastrophe & tail-event exposure (the dominant risk): property reinsurance, retro, political violence, aviation war, cyber — the book is built from fat-tailed lines. Two of the last six quarters were losses; that is the base rate, not a fluke.
• Earnings lumpiness meets a thin tape: ≤5 covering analysts and a $2.1B cap mean a bad print re-prices with little sell-side cushion.
• Capital-allocation leverage: FY25 buybacks were part-funded by $393M of new short-term debt during a −$408M OCF year; if a cat year lands on that structure, the buyback (the core of the bull case) stops first.
• Pricing-cycle turn: specialty/reinsurance rates are cyclical; capacity inflows after benign years compress the ROE that justifies ≥1.0× book.
• Short public history + rebrand: IPO June 2023, renamed May 2026 — limited through-cycle evidence as a public company, and the file offers no rationale for the name change.
• Data-quality caveats (this file): empty segment, geography, and peer tables; revenue-estimate basis inconsistent with the income statement; two different EPS bases (operating vs GAAP); 52-week ranges disagree between the quote and tech blocks. Every number above is from the file; these are its gaps.
• No expert coverage: there is no panel view — bull or bear — to check this analysis against; conviction is structurally capped.

12. Verdict, position sizing & monitoring

Watch. Pelagos is the kind of name a value screen is supposed to surface: ~1.0× book, ~6.5× earnings, 16% ROE, a 2.4% dividend, and a share count down 20% in three years — with essentially zero net debt and a 0.30 beta. But the entry is wrong today: the stock sits 4% from its high, ~10% above the thin Street consensus ($22.25), our own base-case fair value (~$24, anchored to book) offers −3%, hurricane season is just starting, and the FY25 combination of negative operating cash flow and debt-funded buybacks deserves one more clean quarter of evidence. We want the business at a price that pays for the tail risk; that price is ~$21 (≈0.85× book) — or today's price after a benign cat season and a positive-OCF print.

• Sizing (if triggered): small — ~1–2% in an income/value sleeve. Low beta is not low risk here; the risk arrives in lumps, so size for a −$1 EPS quarter.
• Monitoring: re-underwrite on the §10 tripwires; formal re-score at the 2026-08-12 print. This verdict is logged as a tracked Synthos call as of 2026-07-06 at $24.63.
• Single biggest risk: a heavy catastrophe quarter — the same event that produced Q4-24's −$1.09 EPS — landing on a debt-assisted buyback structure at a price already above Street targets.

Provenance & disclosures

• Traceability: 0 KB claims, 0 voices — no expert-panel coverage of PLGO. This note is fundamentals-driven from the FMP data file; nothing herein cites expert authority because none exists in the KB for this ticker. kb_net_conviction is null because there is nothing to aggregate — not because it was omitted.
• Data as-of: fundamentals 2026-03-31 (Q1 2026) · estimates & prices 2026-07-06 (data-file pull) · KB claims: none. Forward figures are analyst consensus (FMP, ≤5 analysts) and are labeled as estimates.
• Valuation method: book-value / earnings-multiple anchor (1.0× BVPS $24.25, cross-checked vs 6.5× 2026E EPS $3.66), not a DCF — FY25 operating cash flow was negative and insurance cash flows are timing-lumpy, so a cash-flow DCF would be false precision. Assumptions are shown in §3.
• Data-quality caveats: segment, geography, and peer tables are empty in the file; revenue estimates appear to be on a different (gross-premium) basis than income-statement revenue; earnings-calendar EPS is operating-basis vs GAAP in the statements; the quote and tech blocks disagree on the 52-week low ($14.80 vs $20.14 — different windows). FY23 net income contains a very large one-time/non-cash gain and is not a valid comp.
• Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
• Version: 2026-07-06. Prior versions available via the deep-dive version dropdown ("based on the info at the time").